Listen
KISQALI (ribociclib) - Early breast cancer
Opinions on drugs -
Posted on
Jul 24 2025
Reason for request
Inclusion on list
Summary of opinion
Unfavourable opinion for reimbursement of KISQALI in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence.
Clinical Benefit
| Insufficient |
The clinical benefit of KISQALI 200 mg (ribociclib) film-coated tablets is insufficient in the MA indication to justify public funding. |
Clinical Added Value
| Not applicable |
Documents
English version
Contact Us
Évaluation des médicaments
